RBC Capital Upgrades Sarepta (SRPT) to Outperform; Becomes Attractive M&A Target

Sarepta (SRPT) Wins Key PTO Decision on Composition of Matter Patents - Oppenheimer

Oppenheimer analyst Michelle Gilson notes US Patent and Trademark Office ruled in favor of Sarepta (NASDAQ: SRPT) for Patents 7,960,541 and 7,807,816 in its patent interference proceeding (interference number 106,008).

Gilson notes these cover composition of matter for eteplirsen, giving the Sarepta freedom to operate... More

Sarepta Therapeutics (SRPT) Confirms Accelerated FDA Approval of Eteplirsen

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for EXONDYS 51 (eteplirsen) as a once weekly intravenous infusion of 30 milligrams per kilogram for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation in the DMD gene that is amenable to exon 51 skipping. This indication is based on an increase in dystrophin in skeletal muscles observed in some patients treated with EXONDYS 51. A clinical benefit of EXONDYS 51 has not been established. Continued approval... More

Sarepta Therapeutic (SRPT) PT Raised to $81 at Needham & Company

Needham & Company analyst Chad Messer reiterated a Buy rating and raised his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $81.00 (from $47.00) following eteplirsen approval.

Messer commented, "The FDA has granted conditional approval to eteplirsen (Exondys 51) stating that data on dystrophin production was "reasonably... More

Sarepta Therapeutics (SRPT) to Hold 4PM ET Investor Call - Bloomberg, Citing PR Agency

Sarepta Therapeutics (NASDAQ: SRPT) to Hold 4PM ET Investor Call - Bloomberg, Citing PR Agency

Leerink Partners Upgrades Sarepta Therapeutic (SRPT) to Market Perform

Leerink Partners upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Underperform to Market Perform with a price target of $50.00 (from $5.00).

Analyst Joseph Schwartz commented, "Sarepta's eteplirsen (Exondys 51, Duchenne Muscular Dystrophy) surprisingly received FDA's accelerated approval (AA), in stark contrast to the FDA's negative commentary... More

Sarepta (SRPT) PT Raised to $76 at Oppenheimer Amid Eteplirsen Approval

Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and raised her price target on Sarepta Therapeutic (NASDAQ: SRPT) to $76.00 (from $60.00) after the FDA announced the approval of eteplirsen (EXONDYS 51) for the treatment of all boys with DMD amenable to Exon 51 skipping.

Gilson... More

Unusual 11 Mid-Day Movers 9/19: (SRPT) (ISLE) (NSAT) Higher; (VICL) (MGT) (MICT) Lower

Sarepta Therapeutics' (Nasdaq: SRPT) 88.6% HIGHER; The U.S. Food and Drug Administration today approved Sarepta Therapeutics' Exondys 51 (eteplirsen) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the population with DMD.

Isle of Capri Casinos, Inc. (Nasdaq: ISLE) 30.2% HIGHER; Eldorado Resorts, Inc. and Isle of Capri Casinos, Inc.... More

Streetinsider.com's Hot Lunchtime Reads 9/19: (PYPL) (WBMD) (SRPT) (FDX)

The following is a list of notable articles to help get you through the lunch hour:WebMD (WBMD) PT Lowered to $63 at Mizuho as New CEO Abruptly Announced ->... More

Sarepta Therapeutic (SRPT) PT Raised to $102 at Baird

(Updated - September 19, 2016 12:23 PM EDT)

Baird reiterated an Outperform rating and raised its price target on Sarepta Therapeutic (NASDAQ: SRPT) to $102.00 (from $23.00) following FDA approval of eteplirsen.

Analyst Brian Skorney commented, "After months of delays, requests for additional data, and... More

SunTrust Upgrades Sarepta Therapeutic (SRPT) to Neutral

SunTrust Robinson Humphrey upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Reduce to Neutral with a price target of $48.00 (from $4.00).

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.

Sarepta Therapeutics (SRPT) Shorts Squeezed After Eteplirsen Receives FDA Approval

Sarepta Therapeutics (NASDAQ: SRPT) shorts were pressured after the FDA approved its DMD drug eteplirsen. The news sent shares up over 90% intraday and caught many shorts sellers off guard. According to Nasdaq data from August 31st, short interest was 14.8 million shares, or... More

Sarepta Therapeutics (SRPT) Pushes to Highs Following FDA Approval; +90%

Sarepta Therapeutics (NASDAQ: SRPT) trading at the highs of the session following FDA approval. Shares are up 90.7%

Piper Jaffray Upgrades Sarepta Therapeutic (SRPT) to Overweight

Piper Jaffray upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Overweight with a price target of $64.00 (from $17.00).

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.

Janney Montgomery Scott Upgrades Sarepta Therapeutic (SRPT) to Buy

Janney Montgomery Scott upgraded Sarepta Therapeutic (NASDAQ: SRPT) from Neutral to Buy with a price target of $65.00.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $28.15 yesterday.

Sarepta Therapeutic (SRPT) Label More Inclusive Than Anticipated - Oppenheimer

Oppenheimer analyst Michelle Gilson reiterated an Outperform rating and $60 price target on Sarepta Therapeutic (NASDAQ: SRPT) after the FDA announced the approval of eteplirsen (EXONDYS51) for the treatment of DMD amenable to Exon 51 skipping.

In conjunction with eteplirsen's accelerated approval, Sarepta will... More